Read the rest here:
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology /...
Related Post
- FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) - February 13th, 2025
- Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26 - February 13th, 2025
- Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia - February 13th, 2025
- Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update - February 13th, 2025
- Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs - February 13th, 2025
- Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - February 13th, 2025
- Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - February 13th, 2025
- Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time - February 13th, 2025
- Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - February 13th, 2025
- Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - February 13th, 2025
- Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit - February 13th, 2025
- Illuccix® Approved in the United Kingdom - February 13th, 2025
- Idorsia publishes the resolutions for the upcoming bondholder meeting - February 13th, 2025
- Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025 - February 13th, 2025
- EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to... - February 13th, 2025
- Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study - February 13th, 2025
- Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in... - February 13th, 2025
- Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results - February 13th, 2025
- PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD - February 13th, 2025
- Cytovation Appoints Martin Dewhurst to its Board of Directors - February 13th, 2025
- Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis - February 11th, 2025
- Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference - February 11th, 2025
- Grace Therapeutics Announces Private Placement Financing of up to $30 Million - February 11th, 2025
- Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience - February 11th, 2025
- IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - February 11th, 2025
- Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy - February 11th, 2025
- Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - February 11th, 2025
- Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial - February 11th, 2025
- Capricor Therapeutics to Participate in Upcoming Investor Conferences - February 11th, 2025
- Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - February 11th, 2025
- Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory... - February 11th, 2025
- Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - February 11th, 2025
- Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol - February 11th, 2025
- Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - February 11th, 2025
- Revolo to Present at the 2025 AAAAI / WAO Joint Congress - February 11th, 2025
- Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - February 11th, 2025
- LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - February 11th, 2025
- Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 11th, 2025
- Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - February 11th, 2025
- CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories - February 6th, 2025
- Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025 - February 6th, 2025
- Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - February 6th, 2025
- Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program - February 6th, 2025
- Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales - February 6th, 2025
- BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors - February 6th, 2025
- North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences - February 6th, 2025
- GUERBET : 2024 revenue. - February 6th, 2025
- Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - February 6th, 2025
- Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - February 6th, 2025
- Shareholding declaration Valneva SE - January 2025 - February 6th, 2025
- CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme - February 6th, 2025
- 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - February 6th, 2025
- Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 6th, 2025
- Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor - February 6th, 2025
- Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board - February 6th, 2025
- PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli - February 6th, 2025
- GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 - February 6th, 2025
- Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative... - February 6th, 2025
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - February 6th, 2025
- Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism - February 4th, 2025
- Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - February 4th, 2025
- Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 4th, 2025
- COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes - February 4th, 2025
- Iantrek Appoints Adam Szaronos as Chief Executive Officer - February 4th, 2025
- Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America - February 4th, 2025
- MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 4th, 2025
- Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC - February 4th, 2025
- IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer... - February 4th, 2025
- Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 4th, 2025
- Allogene Therapeutics Announces Participation in February Investor Conferences - February 4th, 2025
- SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - February 4th, 2025
- Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - February 4th, 2025
- PathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AI - February 4th, 2025
- Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - February 4th, 2025
- Turnstone Biologics Announces Plans to Explore Strategic Alternatives - February 4th, 2025
- Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - February 4th, 2025
- Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - February 4th, 2025
- FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness - February 4th, 2025
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 4th, 2025
- Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update - February 2nd, 2025
Recent Comments